Advertisement


Mary-Ellen Taplin, MD, FASCO, on High-Risk Localized or Locally Advanced Prostate Cancer: PROTEUS Trial

ASCO 2026

Advertisement

Mary-Ellen Taplin, MD, FASCO, of Dana-Farber Cancer Institute, presents the final analysis of the phase III PROTEUS study, which looked at perioperative (neoadjuvant and adjuvant) apalutamide plus androgen-deprivation therapy (ADT) vs placebo and ADT with radical prostatectomy in patients with high-risk localized or locally advanced prostate cancer (Abstract LBA1).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Prostate cancer patients who are diagnosed with localized high-risk disease have high rates of relapse after standard-of-care treatment options of prostatectomy or radiation combined with androgen deprivation therapy. We designed the PROTEUS trial to test the hypothesis that 6 months of apalutamide combined with androgen deprivation therapy, given both before and after prostatectomy and compared to a control arm of placebo and androgen deprivation therapy, would improve two coprimary endpoints. These coprimary endpoints were major pathologic response, which was measured by either a complete response of tumor in the prostate or having a minimal amount of residual disease, less than 5 mm of tumor. And the second coprimary endpoint was metastasis-free survival. So PROTEUS was an international trial. It was done in 18 countries. A total of 2,109 patients were randomly assigned to these two cohorts and then followed, and the median time of follow-up was just over 5 years. When the data read out, what the data showed was that for the apalutamide ADT treatment, there was a ninefold improvement in the primary endpoint of a major pathologic response. This was measured by having no tumor or less than 5 mm of tumor. And there was an exploratory endpoint called residual cancer burden that also measures tumor cellularity and size, and that was 30% for apalutamide androgen deprivation compared with 11% for placebo androgen deprivation. So all of these pathology results show that apalutamide and ADT is killing more cancer cells in the prostate. The other coprimary endpoint is metastasis-free survival, and that was measured by PSMA PET imaging or conventional imaging, and that endpoint showed a 20% improvement for the apalutamide ADT. And in addition, if the MFS was measured by investigator-assessed MFS as opposed to the blinded central reviewer, there was a 24% improvement in MFS. These primary endpoints were supported by positive results in the secondary endpoints, a measure called event-free survival, which is recurrence of prostate cancer by any measure, PSA, local recurrence, any of the imaging that showed it’s also a significant benefit for apalutamide and ADT, with a 29% reduction for the apalutamide compared with the ADT alone. And then another secondary endpoint, which is called time to first subsequent therapy, was markedly positive, with almost a 3-year difference for the patients in the apalutamide ADT cohort needing another treatment. The known side effects of apalutamide, there was an incidence of rash. The rash was generally well controlled with standard algorithms that we use to treat rash that is seen with apalutamide and other stages of prostate cancer. So very excited about these primary and secondary endpoints. The exploratory endpoints support the other endpoints, and we’re very excited about the future work. There was a substudy in which 400 men were assigned to just going to prostatectomy or compared with the PROTEUS regimen, the 6 months of apalutamide and ADT before and after prostatectomy. So that study will read out later this year. We’re excited to see we are hypothesizing even a bigger difference, and the biomarker data will just be incredible. It’s 2,109 men that we will be able to look at metrics of favorable response versus resistance and be able to use generated hypotheses from PROTEUS to plan subsequent neoadjuvant and adjuvant work to improve the cure rates even more.

Related Videos

Gynecologic Cancers

Linda R. Mileshkin, MD, MBBS, FRACP, on Puxitatug Samrotecan for Endometrial or Ovarian Cancer

Linda R. Mileshkin, MD, MBBS, FRACP, of Peter MacCallum Cancer Centre, shares results from the phase I/IIA BLUESTAR study on the safety and efficacy of puxitatug samrotecan, a B7-H4–directed topoisomerase I inhibitor antibody-drug conjugate, in patients with endometrial cancer or ovarian cancer (Abstract 5515). 

Pancreatic Cancer

Asaf Maoz, MD, on Pancreatic Cancer Screening: Potential Blood-Based Biomarkers

Asaf Maoz, MD, of Dana-Farber Cancer Institute, Mass General Brigham, and Harvard Medical School, talks about whether prospective assessment of CA 19-9 has utility as part of pancreatic cancer surveillance among high-risk individuals (Abstract 10527). 

Sarcoma

Mark A. Dickson, MD, on Advanced Dedifferentiated Liposarcoma: SARC041 Trial

Mark A. Dickson, MD, of Memorial Sloan Kettering Cancer Center, presents findings from SARC041, a phase III randomized double-blind study of abemaciclib vs placebo in patients with dedifferentiated liposarcoma; patients who received abemaciclib experienced a statistically significant improvement in progression-free survival (Abstract LBA2).

Lung Cancer

Sanjay Popat, PhD, FRCP, on RET Fusion-Positive NSCLC: First-Line Pralsetinib

Sanjay Popat, PhD, FRCP, of the Royal Marsden Hospital & Institute of Cancer Research, talks about the findings of the phase III AcceleRET-Lung study, which looked at the oral tyrosine kinase inhibitor pralsetinib as first-line therapy for patients with RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC) (Abstract 8504).

Shubham Pant, MD, MBBS, on Novel RAS-Targeting Therapy Daraxonrasib Doubles Overall Survival in Metastatic Pancreatic Cancer

Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses the practice-changing results of the phase III RASolute 302 study, which showed that daraxonrasib doubled median overall survival compared with standard chemotherapy in pretreated metastatic pancreatic cancer (Abstract LBA5).  

Advertisement

Advertisement




Advertisement